SCHEMBL1872205

SCHEMBL1872205

COc1c(N)ncnc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.49
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AURKA O14965 1/20 0.38
MAPT P10636 3/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 2/20 0.34
MAP4K4 O95819 3/20 0.34
ENPP1 P22413 2/20 0.34
NFE2L2 Q16236 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
PI4KB Q9UBF8 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288911 0.84 ALDH1A1 (0.44) PDE5AALDH1A1LMNASMN1; SMN2AURKA
SCHEMBL14782481 0.79 ALDH1A1 (0.47) PDE5AALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL14782257 0.78 PDE5A (0.34) PDE5AALDH1A1MAPTGAAHTT
SCHEMBL7297617 0.77 DHPS (0.58) PDE5AALDH1A1HTTNFE2L2L3MBTL1
SCHEMBL12261633 0.76 ALDH1A1 (0.39) PDE5AALDH1A1LMNASMN1; SMN2AURKA
SCHEMBL9044468 0.76 ALDH1A1 (0.39) PDE5AALDH1A1LMNASMN1; SMN2AURKA
SCHEMBL29636952 0.76 PDE5A (0.46) PDE5AMAP4K4PI4KBL3MBTL1PIK3CD
SCHEMBL16712814 0.76 PDE5A (0.46) PDE5AMAP4K4PI4KBL3MBTL1PIK3CD
SCHEMBL6233405 0.76 PDE5A (0.46) PDE5ALMNAMAPTMAP4K4ADORA2A
SCHEMBL7699473 0.75 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTMAP4K4PI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1529036-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE Degussa AG (DE) 2005-05-11 EP claimed
WO-2004007466-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE DEGUSSA AG (DE) 2004-01-22 WO claimed
EP-4736856-A2 BICYCLIC AMINES AS CDK2 INHIBITORS Incyte Corporation (US) 2026-05-06 EP disclosed
US-12570631-B2 Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk BIOGEN MA INC. (US) 2026-03-10 US disclosed
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 US disclosed
EP-4041731-B1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORP (US) 2026-02-18 EP disclosed
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2026-01-22 US disclosed
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof ACCRO BIOSCIENCE HK LTD (HK) 2026-01-01 US disclosed
US-12466828-B2 Bicyclic amines as CDK2 inhibitors INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
EP-4551559-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF Accro Bioscience (HK) Limited (HK) 2025-05-14 EP disclosed
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2011-03-10 US disclosed
CN-101035780-A Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain MERCK SHARP & DOHME (GB) 2007-09-12 CN disclosed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
EP-1529036-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE Degussa AG (DE) 2005-05-11 EP disclosed
EP-1529036-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE Degussa AG (DE) 2005-05-11 EP disclosed
WO-2004007466-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE DEGUSSA AG (DE) 2004-01-22 WO disclosed
WO-2004007466-A1 METHOD FOR PRODUCING HIGHLY PURE CRYSTALLINE 4-AMINO-5,6-DIMETHOXYPYRIMIDINE DEGUSSA AG (DE) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570631-B2 Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk BTK, LYN, SYK PDE5A 2188/4885ALDH1A1 4560/4885LMNA 1793/4885
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 PDE5A 2296/4885ALDH1A1 2879/4885LMNA 3939/4885
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CCNA1, CDK1, CCNE1 PDE5A 4549/4885ALDH1A1 1613/4885LMNA 887/4885
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CCNA1, CCNE1, CCNA2 PDE5A 4468/4885ALDH1A1 1035/4885LMNA 1093/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 PDE5A 1615/4885ALDH1A1 2211/4885LMNA 2193/4885
US-20260001898-A1 Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof JAK1, JAK2, TYK2 PDE5A 4014/4885ALDH1A1 4319/4885LMNA 3600/4885
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF PDE5A 1786/4885ALDH1A1 1475/4885LMNA 2071/4885
US-12466828-B2 Bicyclic amines as CDK2 inhibitors CDK2, CDK1, CCNI PDE5A 3123/4885ALDH1A1 2576/4885LMNA 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.